Antabio Stock

Antabio is a private biopharmaceutical company developing antibacterial resistance-breakers in areas of highest medical need.

Sign up today and learn more about Antabio Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Antabio Stock

Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. It develops stand-alone inhibitors of bacterial metalloenzymes that can be combined with various antibiotics to restore their activity against the most critical pathogens. The company's novel inhibitor of bacterial Metallo ß-lactamases (“MBLs”) which will be combined with a carbapenem to fill an important gap in the treatment of drug-resistant infections. They develop a novel, safe and efficacious inhibitor of bacterial Metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections. Antabio received a Wellcome Trust Seeding Drug Discovery Award. The company was founded in 2009 and is headquartered in Labege, France.

Funding History

February 2011$1.0M
February 2013$4.7M
November 2013$742K
December 2014$90K
April 2015$1.0M
May 2015$4.0M
July 2017$8.9M
October 2017$7.3M
July 2018$5.2M
January 2020$4.4M
March 2021$900K
June 2022$2.5M
December 2023$25.0M

Management

Chief Scientific Officer

Martin Everett

Non Executive Board member

Helmuth van Es

CEO

Marc Lemonnier

Chief Financial Officer

Gordon Waldron

Chairman of the Board

Gordon Waldron

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo